5-hydroxymethylcytosine Epigenetic Markers in COVID-19-Associated Acute Coronary Syndrome: Insights into Neutrophil Activation and PDE4D Upregulation

Zhongheng Li; Maimaitiyasen Duolikun; Hangyu Chen; Lei Zhang; Yishuo Liu; Ruining Li; Dan Li; Lijie Sun; Long Chen

doi:10.1101/2024.09.09.24313367

Abstract

Background Studies have reported that 5hmC features in cell-free DNA (cfDNA) could serve as early warning biomarkers for the occurrence and progression of COVID-19, as well as myocardial injury. However, its roles in the occurrence and progression of acute coronary syndrome (ACS) following COVID-19 infection have not been fully studied.

Methods Firstly, we used the 5hmC-Seal technique to obtain genome-wide 5hmC profiles from plasma cfDNA of 24 ACS2N patients (individuals experiencing ACS onset within 2 months after COVID-19 infection), 28 ACS2W patients (individuals experiencing ACS onset beyond 2 months after COVID-19 infection), and 16 ACS patients (patients with ACS without COVID-19 infection). Secondly, we performed GO, KEGG analysis on the differentially expressed genes and identified a series of immune and inflammation related genes. Thirdly, the distribution of immune cells in different groups of patients was studied by immune infiltration analysis. Finally, we performed PPI network analysis on these genes to identify potential key target genes.

Results In this study, we firstly found that there was a significant difference in 5hmC levels between ACS2N patients and ACS patients, while the difference between ACS2W and ACS was not significant. Secondly, it was found that neutrophils were abnormally activated in the ACS2N group. Finally, a target gene phosphodiesterase 4D (PDE4D) was found to be highly expressed in the ACS2N group by PPI network analysis of the differential genes and validated with external datasets.

Conclusions Our study suggested that 5hmC markers extracted from plasma cfDNA could differentiate between ACS2N and ACS patients. In addition, we observed that neutrophils exhibited abnormal activation in ACS2N patients. Further analysis showed that COVID-19 infection may affect the occurrence and development of ACS by abnormally up-regulating PDE4D gene expression.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by National Natural Science Foundation of China(8160030583).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was conducted according to the guidelines of the Helsinki Declaration and was approved by the Ethics Committee of Peking University Third Hospital. Written informed consent was obtained from all participants.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes